Haldol Decanoas

Haldol Decanoas is a prescription medication that contains the active ingredient haloperidol decanoate, a long‑acting butyrophenone antipsychotic. It is supplied as an intramuscular injection intended for use in the European market. The formulation provides a depot delivery system that releases haloperidol over several weeks, facilitating maintenance therapy for chronic psychiatric conditions. No specific strength is listed in the available product information currently publicly widely distributed.

Haloperidol decanoate is indicated for several psychiatric conditions where long‑acting antipsychotic therapy is appropriate.

- Schizophrenia, including maintenance treatment after stabilization. - Acute psychotic episodes when oral therapy is not feasible. - Tourette syndrome as an adjunctive option. - Chronic psychotic disorders requiring depot injection. - Situations where patient adherence to daily oral medication is a concern.

The safety profile of haloperidol decanoate includes both frequent and rare adverse events that clinicians monitor during treatment.

Common: - Sedation or drowsiness - Extrapyramidal symptoms such as tremor or rigidity - Dry mouth and increased salivation - Constipation or gastrointestinal discomfort - Weight gain or appetite changes

Serious: - Neuroleptic malignant syndrome - Tardive dyskinesia - Severe hypotension or cardiovascular collapse - Seizures - Agranulocytosis or severe leukopenia

Before initiating haloperidol decanoate, healthcare providers should evaluate several clinical factors to minimize risks.

- History of cardiovascular disease, arrhythmias, or prolonged QT interval. - Existing movement disorders or prior episodes of tardive dyskinesia. - Hepatic or renal impairment that may affect drug metabolism. - Pregnancy, lactation, or plans for conception, given limited safety data. - Concomitant use of other central nervous system depressants. - Elderly patients, especially those with dementia-related psychosis, due to increased sensitivity. - Need for regular monitoring of blood pressure, ECG, and metabolic parameters.

Haloperidol decanoate can interact with other medications, altering its efficacy or safety profile.

Avoid: - Other dopamine antagonists or high‑potency antipsychotics. - Drugs that significantly prolong the QT interval (e.g., certain antiarrhythmics, macrolide antibiotics). - Strong CYP3A4 inhibitors such as ketoconazole or clarithromycin.

Use with caution: - CYP3A4 inducers like carbamazepine, rifampin, or phenytoin. - Central nervous system depressants, including benzodiazepines and opioids. - Anticholinergic agents that may mask extrapyramidal symptoms.